Gemini is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its lead candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD.